i am in, page-5

I can see 40c not $2.00 for now. Risk profile..PSD enjoys growing revenues, a later stage research pipeline, close big pharma ties, a large IP portfolio, FDA approval experience and the credability of an existing licencing deal. PSD's Appointment of Dr Paul ASHTON as MD in late January 2007 removes leadership uncertainty, while new Chairman David Mazzo has big pharma experience. A big pharma licencing deal(Pfizer perhaps) or completion of the $33 million investment by Nordic biotech would lower PSD's risk profile.